Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Hospitalization
Serious outcomes
RCTs
RCT mortality
All outcomes

Feedback
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 paxlovid studies
Outcomes in paxlovid studies. PAXLOVID™ is an investigational SARS-CoV-2 protease inhibitor antiviral therapy combining PF-07321332 and ritonavir.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 95% 1 1,219 Improvement, Studies, Patients Relative Risk, 95% CI Mortality 95% 1 1,219 Hospitalization 85% 1 1,219 RCTs 95% 1 1,219 Early 95% 1 1,219 Paxlovid for COVID-19 c19early.com/pl Dec 5, 2021 Favors paxlovid Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 95% 0.05 [0.00-0.81] death 0/607 10/612 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 95% 0.05 [0.00-0.81] 0/607 10/612 95% improvement All studies 95% 0.05 [0.00-0.81] 0/607 10/612 95% improvement 1 paxlovid COVID-19 study c19early.com/pl Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.10 Effect extraction pre-specified Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 95% 0.05 [0.00-0.81] 0/607 10/612 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 95% 0.05 [0.00-0.81] 0/607 10/612 95% improvement All studies 95% 0.05 [0.00-0.81] 0/607 10/612 95% improvement 1 paxlovid COVID-19 mortality result c19early.com/pl Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.10 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 85% 0.15 [0.06-0.34] hosp. 6/607 41/612 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 85% 0.15 [0.06-0.34] 6/607 41/612 85% improvement All studies 85% 0.15 [0.06-0.34] 6/607 41/612 85% improvement 1 paxlovid COVID-19 hospitalization result c19early.com/pl Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 4.42 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 95% 0.05 [0.00-0.81] death 0/607 10/612 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 95% 0.05 [0.00-0.81] 0/607 10/612 95% improvement All studies 95% 0.05 [0.00-0.81] 0/607 10/612 95% improvement 1 paxlovid COVID-19 serious outcomes c19early.com/pl Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.10 Effect extraction pre-specified Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 95% 0.05 [0.00-0.81] death 0/607 10/612 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 95% 0.05 [0.00-0.81] 0/607 10/612 95% improvement All studies 95% 0.05 [0.00-0.81] 0/607 10/612 95% improvement 1 paxlovid COVID-19 Randomized Controlled Trials c19early.com/pl Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.10 Effect extraction pre-specified Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 95% 0.05 [0.00-0.81] 0/607 10/612 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 95% 0.05 [0.00-0.81] 0/607 10/612 95% improvement All studies 95% 0.05 [0.00-0.81] 0/607 10/612 95% improvement 1 paxlovid COVID-19 RCT mortality result c19early.com/pl Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.10 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 95% 0.05 [0.00-0.81] death 0/607 10/612 Improvement, RR [CI] Treatment Control Pfizer (DB RCT) 93% 0.07 [0.00-1.16] death 0/389 7/385 Pfizer (DB RCT) 85% 0.15 [0.06-0.34] hosp. 6/607 41/612 Pfizer (DB RCT) 89% 0.11 [0.03-0.36] hosp. 3/389 27/385 paxlovid COVID-19 outcomes c19early.com/pl Dec 5, 2021 Favors paxlovid Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit